Mahmoud Aly1, Chaitanya Rojulpote1, Esha Kothekar1, Therese Seierstad2 and Mona-Elisabeth Revheim1,2,3*
1Department of Radiology, Hospital of the University of Pennsylvania, USA 2Division of Radiology and Nuclear Medicine, Oslo University Hospital, Norway 3Institute of Clinical Medicine, University of Oslo, NorwayFulltext PDF
A 52 years old male patient, with a history of Gastrointestinal Stromal Tumor (GIST) in the small intestines with metastasis to the liver and peritoneum, with pathology showing mutation type Exon11. The patient underwent 18F-FDG PET/CT scan that showed lesions with moderate FDG uptake. The patient was given Sunitinib 50 mg p.os and a 18F-FDG PET/CT scan performed two weeks later showed marked reduced FDG uptake in all lesions. However, due to side effects, Sunitinib was first discontinued and then restarted after three weeks with 25 mg (half dose). A follow-up 18F-FDG PET/ CT scan three months later showed stable disease but high FDG uptake in multiple cervical, axillary and mediastinal lymph nodes.
Sarcoid; FDG PET/CT; GIST; RTK; Sunitinib
Aly M, Rojulpote C, Kothekar E, Seierstad T, Revheim M-E. Sarcoid-like Reaction Detected by 18F-FDG PET/ CT in a Patient with Gastrointestinal Stromal Tumor (GIST) Post-Therapy with Multi-Targeted Receptor Tyrosine Kinase (RTK) Inhibitor Sunitinib. Clin Oncol. 2020; 5: 1691.